Rate My Professor Simon Satchell

Professor Simon Satchell is Professor of Renal and Vascular Medicine in Bristol Medical School (Translational Health Sciences) at the University of Bristol. He earned his MBBS from the University of London and PhD from the University of Bristol. Satchell holds Membership of the Royal College of Physicians (MRCP) and Certificates of Completion of Specialist Training (CCST) in Renal Medicine and General Medicine. His career at the University of Bristol has focused on advancing understanding of renal vascular biology through innovative research methodologies.

Satchell leads the vascular biology research group within the Academic Renal Unit, specializing in glomerular endothelial cells (GEnC) that form the innermost layer of the glomerular capillary wall, crucial for the filtration barrier. His team pioneered the first conditionally immortalized human GEnC lines (ciGEnCs) worldwide, allowing detailed examination of fenestrations (60-80nm pores enabling high hydraulic conductivity), the protective glycocalyx layer preventing albuminuria, and tissue-specific functions. Ongoing projects investigate glycocalyx disruption by heparanase and diabetes, fenestration regulation and ultrastructure, barrier modulation by VEGF and angiopoietins, anti-proteinuric effects of interferon beta, and GEnC-podocyte interactions via coculture and shear stress models. These efforts target pathology in proteinuric kidney diseases and diabetes. Key recent publications encompass 'Podocyte-directed VEGFC gene therapy prevents increased glomerular permeability and glycocalyx damage in experimental type 1 diabetes' (Molecular Therapy, 2026), 'Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian Randomisation study' (BMJ Open, 2025), and 'Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy' (Journal of Translational Autoimmunity, 2026). Satchell has secured grants including £193,000 from Kidney Research UK (2024) for diabetic kidney disease targets and British Heart Foundation funding for endothelial glycocalyx restoration.